Question 1

What is Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics is a Company.

Question 2

How often does Atara Biotherapeutics appear in global news?

Accepted Answer

Tracked across 13 news events drawn from 177 articles.

Question 3

When was Atara Biotherapeutics first tracked by Ergen?

Accepted Answer

First tracked on May 15, 2025.

Question 4

When was Atara Biotherapeutics last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is Atara Biotherapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: -4 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Atara Biotherapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 13 events.

Question 7

What is the most recent event involving Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics Class Action Lawsuit (May 01, 2026, 6 articles).

Question 8

Who is Atara Biotherapeutics most connected to?

Accepted Answer

Top relationships: United States — Food and Drug Administration, United States — Food and Drug Administration.

Question 9

How did the "Atara Biotherapeutics Class Action Lawsuit" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. Its stock price experienced significant declines following FDA decisions.

Question 10

How did the "Calidi Biotherapeutics investor webinar" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics is hosting an investor webinar to present its RedTail platform and CLD-401 candidate, aiming to attract investors and drive shareholder value.

Question 11

How did the "Sernova_Biotherapeutics gets FDA Orphan Drug" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics received Orphan Drug Designation from the United States — Food and Drug Administration for its autologous islet transplantation (AIT) for the prevention of diabetes due to total pancreatectomy. This designation provides potential market exclusivity and development incentives, enhancing the company's position in regenerative medicine.

Question 12

How did the "Atara Biotherapeutics Securities Fraud Lawsuits" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics is the defendant in multiple securities fraud class action lawsuits due to alleged misleading statements about its manufacturing issues and the regulatory prospects of its drug tabelecleucel, leading to investor losses.

Question 13

How did the "Arcutis Grants Stock to Employees" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics granted restricted stock units to newly hired employees as an inducement for employment, which is a common practice for attracting talent and can positively impact employee retention and motivation.

Question 14

How did the "Brunkow, Ramsdell, Sakaguchi Win Nobel Medicine" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics, co-founded by Fred Ramsdell, is actively developing therapies based on the discoveries of regulatory T cells, with support from Regeneron, indicating potential for future market clearance.

Question 15

How did the "Multiple Class Action Lawsuits Filed" event impact Atara Biotherapeutics?

Accepted Answer

Atara Biotherapeutics is involved in a class action lawsuit due to allegations that manufacturing issues and deficiencies in the ALLELE study made FDA approval of tabelecleucel BLA unlikely, and that its regulatory prospects were overstated.

Question 16

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.